Treatment of hyperlipidemia in cardiac transplant recipients

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 200-210

  Bilchick, Kenneth C ^a   Henrikson, Charles A ^a   Skojec, Diane ^a   Kasper, Edward K ^a   Blumenthal, Roger S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CERIVASTATIN; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; MEVALONIC ACID; MEVINOLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; PREDNISOLONE; PREDNISONE; PROTEINASE INHIBITOR; RAPAMNNE; RAPAMYCIN; ROSUVASTATIN; SIMVASTATIN; STATIN; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL;

APHERESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG CONTRAINDICATION; ENDOTHELIUM; EPIDEMIOLOGICAL DATA; FLUSHING; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; MUSCLE TOXICITY; MYOPATHY; MYOSITIS; NEPHROTOXICITY; NONHUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RECIPIENT; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT;

EID: 4143116764     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.050     Document Type: Article

References (81)

1. Rudas L., Pflugfelder P.W., McKenzie F.N., et al. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol. 66:1990;1135-1138
2. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627
3. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation a four-year randomized trial. Circulation. 96:1997;1398-1402
4. McGiffin D.C., Savunen T., Kirklin J.K., et al. Cardiac transplant coronary artery disease a multivariable analysis of pretransplantation risk factors for disease development and morbid events. J Thorac Cardiovasc Surg. 109:1995;1081-1088
5. Gao S.Z., Schroeder J.S., Alderman E.L., et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation. 76:1987;V56-61
6. Carrier M., Rivard M., Kostuk W., et al. The Canadian Study of Cardiac Transplantation atherosclerosis. Investigators of the CASCADE Study. Can J Cardiol. 15:1999;1337-1344
7. Simvastatin prescribing information. Available at: http://www.zocor.com. Accessed July 1, 2003
8. International Society of Heart and Lung Transplantation (ISHLT). Available at: http://www.ishlt.org. Accessed July 1, 2003
9. United Network for Organ Sharing (UNOS). Available at: http://www.unos.org. Accessed July 1, 2003
10. Ballantyne C.M., Podet E.J., Patsch W.P., et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 262:1989;53-56
11. Kobashigawa J.A., Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation. 63:1997;331-338
12. Stamler J.S., Vaughan D.E., Rudd M.A., et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol. 62:1988;1268-1272
13. Akhlaghi F., Jackson C.H., Parameshwar J., et al. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation. 73:2002;1258-1264
14. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 71:2001;271-280
15. Kahan B.D. Immunosuppressive effects and safety of a sirolimus/ cyclosporine combination regimen for renal transplantation. Transplantation. 66:1998;1040-1066
16. CellCept product information. Available at: http://www.rocheusa.com/ products/cellcept/pi.html. Accessed July 1, 2003
17. Davis S.F., Yeung A.C., Meredith I.T., et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation. 93:1996;457-462
18. Weis M., Pehlivanli S., Meiser B.M., et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol. 38:2001;814-818
19. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 101:1998;2711-2719
20. Cutts J.L., Bankhurst A.D. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol. 145:1990;244-252
21. Kwak B., Mulhaupt F., Myit S., et al. Statins as a newly recognized type of immunomodulator. Nat Med. 6:2000;1399-1402
22. Muldoon M.F., Flory J.D., Marsland A., et al. Effects of lovastatin on the immune system. Am J Cardiol. 80:1997;1391-1394
23. McPherson R., Tsoukas C., Baines M.G., et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol. 13:1993;439-444
24. Katznelson S., Wang X.M., Chia D., et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 17:1998;335-340
25. Kurakata S., Kada M., Shimada Y., et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology. 34:1996;51-61
26. Akhlaghi F., Ashley J., Keogh A., et al. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Ther Drug Monit. 21:1999;8-16
27. Kuo P.C., Kirshenbaum J.M., Gordon J., et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol. 64:1989;631-635
28. Kobashigawa J.A., Murphy F.L., Stevenson L.W., et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation. 82:1990;IV281-283
29. Ballantyne C.M., Radovancevic B., Farmer J.A., et al. Hyperlipidemia after heart transplantation report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 19:1992;1315-1321
30. Wenke K. Simvastatin initiated early after heart transplantation 8-year prospective experience. Circulation. 107:2003;1-5
31. Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37
32. Mehra M.R., Uber P.A., Vivekananthan K., et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol. 40:2002;1609-1614
33. MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22
34. Magnani G, Carinci V, Magelli C, et al. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 2000;19:710-5
35. Patel D.N., Pagani F.D., Koelling T.M., et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant. 21:2002;204-210
36. Ballantyne C.M. Statins after cardiac transplantation which statin, what dose, and how low should we go? J Heart Lung Transplant. 19:2000;515-517
37. Marx N., Kehrle B., Kohlhammer K., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 90:2002;703-710
38. Peters J.R., Kubo S.H., Olivari M.T., et al. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil ± lovastatin. Am J Cardiol. 71:1993;1485-1488
39. Pflugfelder P.W., Huff M., Oskalns R., et al. Cholesterol-lowering therapy after heart transplantation a 12-month randomized trial. J Heart Lung Transplant. 14:1995;613-622
40. Stapleton D.D., Mehra M.R., Dumas D., et al. Lipid-lowering therapy and long-term survival in heart transplantation. Am J Cardiol. 80:1997;802-805
41. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 346:2002;539-540
42. Pasternak R.C., Smith S.C. Jr, Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 40:2002;567-572
43. Thompson P.D., Zmuda J.M., Domalik L.J., et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 46:1997;1206-1210
44. Morita I., Sato I., Ma L., et al. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin. Endothelium. 5:1997;107-113
45. De Pinieux G., Chariot P., Ammi-Said M., et al. Lipid-lowering drugs and mitochondrial function effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 42:1996;333-337
46. Watts G.F., Castelluccio C., Rice-Evans C., et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 46:1993;1055-1057
47. Laaksonen R., Jokelainen K., Sahi T., et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 57:1995;62-66
48. Hussar D. The statins. Drug Advisor. 1:2002;1-4
49. Olbricht C., Wanner C., Eisenhauer T., et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 62:1997;311-321
50. Yamazaki M., Akiyama S., Ni'inuma K., et al. Biliary excretion of pravastatin in rats contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 25:1997;1123-1129
51. Bramow S, Ott P, Thomsen NF, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001;89:133-9
52. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996;148:1237-47
53. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA. 289:2003;1681-1690
54. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 137:2002;581-585
55. Grundy S.M. Can statins cause chronic low-grade myopathy? Ann Intern Med. 137:2002;617-618
56. Prueksaritanont T., Zhao J.J., Ma B., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 301:2002;1042-1051
57. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 30:2002;1280-1287
58. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother. 35:2001;908-917
59. Alonso-Galicia M., Frohlich B., Roman R.J. Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. Hypertension. 31:1998;232-236
60. Boissonnat P., Salen P., Guidollet J., et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation. 58:1994;245-247
61. Broeders N., Knoop C., Antoine M., et al. Fibrate-induced increase in blood urea and creatinine is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 15:2000;1993-1999
62. Devuyst O., Goffin E., Pirson Y., et al. Creatinine rise after fibrate therapy in renal graft recipients. Lancet. 341:1993;840
63. Chan T.M., Cheng I.K., Tam S.C. Hyperlipidemia after renal transplantation treatment with gemfibrozil. Nephron. 67:1994;317-321
64. Knight R.J., Vathsala A., Schoenberg L., et al. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation. 53:1992;224-225
65. Uzark K., Crowley D., Callow L., et al. Hypercholesterolemia after cardiac transplantation in children. Am J Cardiol. 66:1990;1385-1387
66. Henkin Y., Oberman A., Hurst D.C., et al. Niacin revisited clinical observations on an important but underutilized drug. Am J Med. 91:1991;239-246
67. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592
68. Kos Pharmaceuticals. Niaspan prescribing information. Available at: http://www.niaspan.com. Accessed July 1, 2003
69. Andreassen A.K., Hartmann A., Offstad J., et al. Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol. 29:1997;1324-1331
70. Holm T., Andreassen A.K., Aukrust P., et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J. 22:2001;428-436
71. Fleischhauer F.J., Yan W.D., Fischell T.A. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 21:1993;982-989
72. Durrington P.N., Bhatnagar D., Mackness M.I., et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 85:2001;544-548
73. Keogh A., Day R., Critchley L., et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc. 20:1988;27-30
74. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 40:2002;2125-2134
75. Ezetimibe prescribing information. Available at: http://www.zetia.com. Accessed July 1, 2003
76. MoriartyPM, GibsonCA. Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Curr Atheroscler Rep 2001;156-62
77. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 82:2003;1489-1495
78. Jaeger B.R., Schirmer J., Thiery J., et al. Coronary risk factor man-agement for the prevention and treatment of graft vessel disease in heart transplant patients. Ther Apher. 3:1999;214-218
79. Park J.W., Merz M., Braun P. Regression of transplant coronary artery disease during chronic low- density lipoprotein-apheresis. J Heart Lung Transplant. 16:1997;290-297
80. Gadbut A.P., Caruso A.P., Galper J.B. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 27:1995;2397-2402
81. Masters B.A., Palmoski M.J., Flint O.P., et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 131:1995;163-174